AUTHOR AND EDITOR INFORMATION

Section 1 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

INTRODUCTION

Section 2 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

Background

Amyloidosis is a generic term that signifies the abnormal extracellular tissue deposition of one of a family of biochemically unrelated proteins that share certain characteristic staining properties, including apple-green birefringence of Congo red–stained preparations viewed under polarizing light. Under electron microscopy (EM), amyloid deposits are composed of linear, nonbranching, aggregated fibrils that are 7.5-10 nm thick of indefinite length arranged in a loose meshwork.

X-ray diffraction crystallography and infrared spectroscopy reveal that these fibrils have a meridional, antiparallel, beta-pleated sheet configuration, with polypeptide chains arranged perpendicular to the long axis of the fibrils.

Amyloid deposits contain (in addition to the fibrillar component) a nonfibrillar protein referred to as amyloid-P (Am-P). This protein is identical to normal plasma globulin, known as serum amyloid-P (SAP). Am-P constitutes 14% of the dry weight of amyloid. This protein is also found in the microfibrillar sheath of elastic fibers. SAP is closely related to the acute phase reactant C-reactive protein (CRP) and has been shown to be an elastase inhibitor.

The SAP and the beta-pleated sheet configurations are thought to protect amyloid deposits from degradation and phagocytosis, leading to persistence of the deposits.

Macular amyloidosis (MA) has been reported in association with Sipple syndrome. The cardinal triad of this autosomal dominant syndrome is medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism.

Pathophysiology

Amyloid deposits in MA and lichen amyloidosis (LA) bind to antikeratin antibodies. These deposits contain sulfhydryl groups pointing to altered keratin as a source for these deposits. Apaydin et al found no differences in staining characteristics of cytokeratins between MA and LA. Interestingly, in their study, all the cytokeratins detected in amyloid deposits were of basic type (type II). This may be because, in amyloidogenesis, acidic cytokeratins such as cytokeratin 14 are degraded faster than basic types.

The exact origin of amyloid deposits in MA has not been determined. Two theories have been proposed to explain the origin of the amyloid deposits. These theories are not mutually exclusive, and both could be possible.

Fibrillar body theory

This theory proposed by Hashimoto suggests that the necrotic epidermal cells (colloid bodies) are transformed into amyloid by dermal macrophages and fibroblasts by a process called filamentous degeneration. The absence of amyloid deposits in other dermatoses with colloid bodies (eg, lichen planus) is explained by the brisk inflammatory reaction clearing them promptly in lichen planus, while the lack of inflammatory cells leads to the formation of amyloid deposits in MA. This theory does not explain how the alpha type of keratin tertiary structure is degraded and converted into the beta-pleated sheet configuration of amyloid.

Secretory theory

This theory proposed by Yamagihara et al suggests that the amyloid in MA is secreted by disrupted basal cells and is assembled at the dermoepidermal junction (DEJ).

Race

The incidence of MA is more common among Asians, Middle Easterners, and South Americans than in other people.

Sex

In many studies, MA seems to affect women more frequently than men.

Age

MA is a disease of the adult population.

CLINICAL

Section 3 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

History

MA is a pruritic eruption that is variable in severity. Frequently, patients seek medical attention because of the hyperpigmentation.

Physical

MA is a pruritic eruption consisting of small, dusky-brown or grayish pigmented macules distributed symmetrically over the upper back and, in some patients, the arms.

Although a reticulated or rippled pattern of pigmentation has been emphasized as a characteristic and diagnostic feature of MA, in 2 case series, less than 50% of patients had this feature.

Causes

Constant friction and rubbing with a nylon brush or towel may cause MA.

DIFFERENTIALS

Section 4 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

Other Problems to be Considered

Poikiloderma secondary to mycosis fungoides, dermatomyositis, and scleroderma

WORKUP

Section 5 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

Procedures

• A skin biopsy may be performed.

Histologic Findings

Many stains can demonstrate amyloid deposits in the skin. The best known is the Congo red stain, which under polarizing light gives apple-green birefringence. Other stains include periodic acid-Schiff (PAS); methyl violet; crystal violet; various cotton dyes (eg, pagoda red, Sirius red); and the fluorescent dyes, thioflavin-T and Phorwhite BBU.

In MA, the amyloid deposits are usually found within the dermal papillae. The amyloid deposits are usually globular, resembling colloid bodies, and they may be in contact with basal cells at the DEJ. The deposits can be minute, escaping detection. For this reason, MA is part of the differential diagnosis for the "normal skin" slide, sometimes called invisible dermatosis. Minimal epidermal changes, such as hyperkeratosis and hypergranulosis, are occasionally observed.

TREATMENT

Section 6 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

Medical Care

• Because of the growing appreciation of the importance of pruritus as the primary trigger for the deposition of amyloid, treatment modalities are directed toward the relief of pruritus in MA and LA.
• • Sedating antihistamines have been found to be moderately effective.
  • Topical dimethyl sulfoxide (DMSO), a chemical solvent, and intralesional steroids are beneficial if combined with other modalities. DMSO has been used with moderate success, but failures have also been reported. Pandhi et al reported a lack of effect with DMSO treatment for cutaneous amyloidosis.
  • Treatment with ultraviolet B (UV-B) light can provide symptomatic relief.
  • Sawamura et al reported satisfying improvement of LA with pulsed dye laser therapy. Both pruritus and the papular eruption of LA improved.

Surgical Care

• Aggressive strategies proposed for the removal of amyloid include laser vaporization, dermabrasion, and excision of individual lesions. However, lesions and pruritus usually promptly recur after these treatments.
• Electrodesiccation and curettage provided an acceptable result in one report.

MEDICATION

Section 7 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

The goal of pharmacotherapy is to reduce morbidity.

Drug Category: Antihistamines

These agents act by competitive inhibition of histamine at the H1 receptor. They may control itching by blocking effects of endogenously released histamine.

Drug Name	Diphenhydramine (Benadryl, Belix)
Description	For symptomatic relief of pruritus caused by endogenous release of histamine.
Adult Dose	25-50 mg PO tid/qid; not to exceed 400 mg/d
Pediatric Dose	12.5-25 mg PO tid/qid or 5 mg/kg/d or 150 mg/m2/d PO divided tid/qid; not to exceed 300 mg/d
Contraindications	Documented hypersensitivity; MAOIs
Interactions	Potentiates effect of CNS depressants; because of alcohol content, do not give syr dosage form to patient taking medications that can cause disulfiramlike reactions
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Drowsiness, dizziness, and dryness of mouth are the most common adverse effects; may exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, and urinary tract obstruction

Drug Category: Topical anti-inflammatory agents

This industrial solvent has been used with mixed results.

FOLLOW-UP

Section 8 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

Prognosis

• The treatment of MA is disappointing, and the disease is chronic.

MULTIMEDIA

Section 9 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

Media file 1:  Reddish brown patch on the back characteristic of macular amyloidosis. Courtesy of Hon Pak, MD, and reviewed by Ross Levy, MD.
	View Full Size Image
Media type:  Photo

Media file 2:  Another patient with macular amyloidosis on the back. Courtesy of Hon Pak, MD, and reviewed by Ross Levy, MD.
	View Full Size Image
Media type:  Photo

Media file 3:  Reticulated pattern of pigmentation on the shoulder of a patient with macular amyloidosis. Courtesy of Hon Pak, MD, and reviewed by Ross Levy, MD.
	View Full Size Image
Media type:  Photo

Media file 4:  Close-up of the above patient's eruption. Courtesy of Hon Pak, MD, and reviewed by Ross Levy, MD.
	View Full Size Image
Media type:  Photo

REFERENCES

Section 10 of 10

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Multimedia
• References

• Apaydin R, Gürbüz Y, Bayramgürler D, et al. Cytokeratin expression in lichen amyloidosus and macular amyloidosis. J Eur Acad Dermatol Venereol. May 2004;18(3):305-9. [Medline].
• Black MM, Jones EW. Macular amyloidosis. A study of 21 cases with special reference to the role of the epidermis in its histogenesis. Br J Dermatol. Mar 1971;84(3):199-209. [Medline].
• Breathnach SM, Bhogal B, Dyck RF, et al. Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis. Br J Dermatol. Aug 1981;105(2):115-24. [Medline].
• Breathnach SM, Melrose SM, Bhogal B, et al. Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature. Oct 22 1981;293(5834):652-4. [Medline].
• Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol. Jan 1988;18(1 Pt 1):1-16. [Medline].
• Brownstein MH, Hashimoto K, Greenwald G. Biphasic amyloidosis: link between macular and lichenoid forms. Arch Dermatol. Sep 1972;106(3):419. [Medline].
• Cortes A. Primary cutaneous amyloidosis. Dermatologica. 1969;139(2):109-14. [Medline].
• Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem. Nov 1968;16(11):673-7. [Medline].
• Eriksson S, Janciauskiene S, Merlini G. The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils. J Intern Med. Feb 1995;237(2):143-9. [Medline].
• Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. Jun 5 1980;302(23):1283-92. [Medline].
• Hashimoto K, Kobayashi H. Histogenesis of amyloid in the skin. Am J Dermatopathol. Summer 1980;2(2):165-71. [Medline].
• Hashimoto K, Ito K, Kumakiri M, Headington J. Nylon brush macular amyloidosis. Arch Dermatol. May 1987;123(5):633-7. [Medline].
• Horiguchi Y, Fine JD, Leigh IM, et al. Lamina densa malformation involved in histogenesis of primary localized cutaneous amyloidosis. J Invest Dermatol. Jul 1992;99(1):12-8. [Medline].
• Hsieh SD, Yamamoto R, Saito K, et al. Amyloidosis presented with whitening and loss of hair which improved after dimethylsulfoxide (DMSO) treatment. Jpn J Med. Aug 1987;26(3):393-5. [Medline].
• Hudson LD. Macular amyloidosis: treatment with ultraviolet B. Cutis. Jul 1986;38(1):61-2. [Medline].
• Kibbi AG, Rubeiz NG, Zaynoun ST, Kurban AK. Primary localized cutaneous amyloidosis. Int J Dermatol. Feb 1992;31(2):95-8. [Medline].
• Kobayashi H, Hashimoto K. Amyloidogenesis in organ-limited cutaneous amyloidosis: an antigenic identity between epidermal keratin and skin amyloid. J Invest Dermatol. Jan 1983;80(1):66-72. [Medline].
• Kurban AK, Malak JA, Afifi AK, Mire J. Primary localized macular cutaneous amyloidosis: histochemistry andelectron microscopy. Br J Dermatol. Jul 1971;85(1):52-60. [Medline].
• Lambert WC. Cutaneous deposition disorders. In: Farmer ER, Hood AF, eds. Pathology of the Skin. Norwalk, Conn: Appleton & Lange; 1990:. 432-50.
• Li JJ, McAdam KP. Human amyloid P component: an elastase inhibitor. Scand J Immunol. Sep 1984;20(3):219-26. [Medline].
• Lim KB, Tan SH, Tan KT. Lack of effect of dimethyl sulphoxide (DMSO) on amyloid deposits in lichenamyloidosis. Br J Dermatol. Sep 1988;119(3):409-10. [Medline].
• Monfrecola G, Iandoli R, Bruno G, Martellotta D. Lichen amyloidosus: a new therapeutic approach. Acta Derm Venereol. 1985;65(5):453-5. [Medline].
• Ozkaya-Bayazit E, Kavak A, Gungor H, Ozarmagan G. Intermittent use of topical dimethyl sulfoxide in macular and papularamyloidosis. Int J Dermatol. Dec 1998;37(12):949-54. [Medline].
• Piette WW. Myeloma, paraproteinemias, and the skin. Med Clin North Am. Jan 1986;70(1):155-76. [Medline].
• Ruzicka T, Donhauser G, Linke RP, et al. [Cutaneous amyloidoses]. Hautarzt. May 1990;41(5):245-55. [Medline].
• Sawamura D, Sato-Matsumura KC, Shibaki A, et al. A case of lichen amyloidosis treated with pulsed dye laser. J Eur Acad Dermatol Venereol. Mar 2005;19(2):262-3. [Medline].
• Shanon J, Sagher F. Interscapular cutaneous amyloidosis. Arch Dermatol. Aug 1970;102(2):195-8. [Medline].
• Shirahama T, Cohen AS. High-resolution electron microscopic analysis of the amyloid fibril. J Cell Biol. Jun 1967;33(3):679-708. [Medline].
• Vestey JP, Tidman MJ, Mclaren KM. Primary nodular cutaneous amyloidosis--long-term follow-up and treatment. Clin Exp Dermatol. Mar 1994;19(2):159-62. [Medline].
• Weyers W, Weyers I, Bonczkowitz M, et al. Lichen amyloidosus: a consequence of scratching. J Am Acad Dermatol. Dec 1997;37(6):923-8. [Medline].
• Wolf M, Tolmach JA. Macular amyloidosis. Arch Dermatol. Mar 1969;99(3):373-4. [Medline].
• Yamagihara M, Kitajima Y, Yaoita H. Ultrastructural observation of the relationship between amyloid filaments and half desmosomes in macular amyloidosis [abstract]. J Cutan Pathol. 1980;7:7:213.
• al-Ratrout JT, Satti MB. Primary localized cutaneous amyloidosis: a clinicopathologic study from Saudi Arabia. Int J Dermatol. Jun 1997;36(6):428-34. [Medline].
• de Argila D, Ortiz-Romero PL, Ortiz-Frutos J, et al. Cutaneous macular amyloidosis associated with multiple endocrine neoplasia 2A. Clin Exp Dermatol. Jul 1996;21(4):313-4. [Medline].

Article Last Updated: Mar 7, 2007